Tepotinib-induced interstitial lung disease in a patient with adenosquamous lung carcinoma

We report a case of drug-induced lung injury in an 88-year-old man with non-small cell lung cancer harboring an MET exon 14 skipping mutation. The patient developed dyspnea and new ground-glass opacities shortly after the initiation of tepotinib, an oral MET-tyrosine kinase inhibitor (MET-TKI). Clinical findings and laboratory data supported the diagnosis of tepotinib-induced interstitial lung disease (ILD). High-dose corticosteroid therapy led to improvement, and the patient was discharged. This case underscores the potential of early onset ILD with tepotinib, especially in patients with possible pre-existing ILD. Close monitoring and early intervention are essential, and further studies are needed to clarify the risk factors for MET-TKI-induced ILD.